Cargando…

Reduced Intensity Allogeneic Hematopoietic Cell Transplantation using Fludarabine-Melphalan conditioning for Treatment of Mature T-cell Lymphomas

Among non-Hodgkin lymphoma subtypes, T-cell phenotype confers a poor clinical prognosis. For more aggressive histologies, patients frequently present with advanced disease that is inherently chemoresistant. For cutaneous histologies, disease progresses less rapidly, but is debilitating and often inc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Delioukina, Maria, Zain, Jasmine, Palmer, Joycelynne M., Tsai, Nicole, Thomas, Sandra, Forman, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130104/ https://www.ncbi.nlm.nih.gov/pubmed/21358679 http://dx.doi.org/10.1038/bmt.2011.16

Ejemplares similares

Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation
por: Duque-Afonso, Jesús, et al.
Publicado: (2020)

Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party
por: Duque-Afonso, Jesus, et al.
Publicado: (2022)

Allogeneic Hematopoietic Cell Transplantation in the Treatment of Chronic Lymphocytic Leukemia: Why and When?
por: Delioukina, Maria L., et al.
Publicado: (2010)

Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation
por: Kamijo, Kimimori, et al.
Publicado: (2023)

Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia
por: Lee, Seung-Shin, et al.
Publicado: (2020)

CD34(+) cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies
por: Holtan, S G, et al.
Publicado: (2010)

Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning
por: Kutzke, Jade L., et al.
Publicado: (2022)

Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
por: Langenhorst, Jurgen B., et al.
Publicado: (2018)

Fludarabine-Melphalan-Campath, Followed by Unmanipulated Peripheral-Blood Haematopoietic Stem Cells, Can Still Cure Lymphoma
por: Avenoso, Daniele, et al.
Publicado: (2023)

Severe fludarabine neurotoxicity after reduced intensity conditioning regimen to allogeneic hematopoietic stem cell transplantation: a case report
por: Annaloro, Claudio, et al.
Publicado: (2015)

Clinical Trial Simulation To Optimize Trial Design for Fludarabine Dosing Strategies in Allogeneic Hematopoietic Cell Transplantation
por: Langenhorst, Jurgen B., et al.
Publicado: (2020)

Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation
por: Mohanan, E, et al.
Publicado: (2017)

Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan–Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation
por: Patel, Khilna, et al.
Publicado: (2016)

Correction: Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation
por: Mohanan, E., et al.
Publicado: (2018)

Treosulfan–fludarabine–thiotepa-based conditioning treatment before allogeneic hematopoietic stem cell transplantation for pediatric patients with hematological malignancies
por: Kalwak, Krzysztof, et al.
Publicado: (2020)

Busulfan and melphalan as conditioning regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia in first complete remission
por: Bueno, Nadjanara Dorna, et al.
Publicado: (2011)

Allogeneic Hematopoietic Stem Cell Transplantation in Cutaneous T-Cell Lymphomas
por: Dumont, Maëlle, et al.
Publicado: (2020)

Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics
por: Hamadani, Mehdi, et al.
Publicado: (2022)

Protective effect of cryotherapy against oral mucositis among allogeneic hematopoietic stem cell transplant recipients using melphalan-based conditioning
por: Oku, Saori, et al.
Publicado: (2023)

Allogeneic hematopoietic stem cell transplantation for primary cutaneous T cell lymphomas
por: Paralkar, Vikram R., et al.
Publicado: (2011)

Peripheral T-cell Lymphomas: Updates in Allogeneic Hematopoietic Stem Cell Transplantation
por: Huang, Wen-Rong, et al.
Publicado: (2018)

Progress in Allogeneic Hematopoietic Cell Transplantation in Adult T-Cell Leukemia-Lymphoma
por: Utsunomiya, Atae
Publicado: (2019)

Feasibility of Non-TBI Conditioning with Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation in Lymphoid Malignancy
por: Shin, Ho Cheol, et al.
Publicado: (2012)

Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide
por: Trunk, Andrew D., et al.
Publicado: (2023)

Clofarabine versus fludarabine‐based reduced‐intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS
por: Chevallier, Patrice, et al.
Publicado: (2016)

Conditioning regimen using busulfan plus melphalan in hematopoietic stem cell transplantation: can this conditioning regimen be used in autologous or allogeneic transplantation for acute leukemia?
por: Lemoli, Roberto M., et al.
Publicado: (2011)

Allogeneic Stem Cell Transplantation for Patients with Advanced Hematological Malignancies: Comparison of Fludarabine-based Reduced Intensity Conditioning versus Myeloablative Conditioning
por: Kim, Inho, et al.
Publicado: (2007)

Comparison of graft versus host disease with three different alemtuzumab schedules in unrelated donor fludarabine and melphalan allografts
por: Green, Kile, et al.
Publicado: (2017)

Allogeneic Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T-cell Lymphoma
por: Peng, Yin-yin, et al.
Publicado: (2021)

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Rodriguez, Tulio E., et al.
Publicado: (2016)

Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma
por: Herrera, Alex F., et al.
Publicado: (2021)

High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation
por: Long-Boyle, Janel R, et al.
Publicado: (2010)

Outcomes of allogeneic hematopoietic stem cell transplantation for lymphomas: a single-institution experience
por: Massoud, Mira Romany, et al.
Publicado: (2016)

Atrial Fibrillation in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
por: Chang, Ellen K., et al.
Publicado: (2021)

Melphalan Culprit or Confounder in Acute Encephalopathy during Autologous Hematopoietic Stem Cell Transplantation?
por: Alayón-Laguer, Diógenes, et al.
Publicado: (2012)

A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT
por: Tran, Misha C., et al.
Publicado: (2022)

Clinical Impact of Melphalan Pharmacokinetics on Transplantation Outcomes in Children Undergoing Hematopoietic Stem Cell Transplantation
por: Maemura, Ryo, et al.
Publicado: (2022)

Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning in allogeneic stem cell transplantation
por: Konopleva, Marina, et al.
Publicado: (2015)

Treating Relapsed/Refractory Acute Myeloid Leukemia with Chidamide, Fludarabine, Cytarabine and Granulocyte-Colony Stimulating Factor with Subsequent Bridging to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
por: Yao, Wen, et al.
Publicado: (2022)

Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis
por: Berning, Philipp, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lcvccerje2fompau96tsog6otc